Casein kinase II phosphorylation of cyclin F at serine 621 regulates the Lys48-ubiquitylation E3 ligase activity of the SCF\(^{(\text{cyclin F})}\) complex

Albert Lee\(^{1,2}\), Stephanie L. Rayner\(^{1,3}\), Alana De Luca\(^{1}\), Serene S. L. Gwee\(^{1}\), Marco Morsch\(^{1}\), Vinod Sundaramoorthy\(^{1}\), Hamideh Shahheydari\(^{1}\), Audrey Ragagnin\(^{1}\), Bingyang Shi\(^{1}\), Shu Yang\(^{1}\), Kelly L. Williams\(^{1}\), Emily K. Don\(^{1}\), Adam K. Walker\(^{1}\), Katharine Y. Zhang\(^{1}\), Justin J. Yerbury\(^{4}\), Nicholas J. Cole\(^{1}\), Julie D. Atkin\(^{1,5}\), Ian P. Blair\(^{1}\), Mark P. Molloy\(^{2,3}\) and Roger S. Chung\(^{1}\)

\(^{1}\)Department of Biomedical Sciences, Centre for Motor Neuron Disease Research, Faculty of Medicine and Health Sciences, Macquarie University, 2 Technology Place, North Ryde, NSW 2109, Australia
\(^{2}\)Australian Proteome Analysis Facility, Research Park Drive, Macquarie University, North Ryde, NSW 2109, Australia
\(^{3}\)Faculty of Science and Engineering, Department of Chemistry and Biomolecular Sciences, Research Park Drive, Macquarie University, North Ryde, NSW 2109, Australia
\(^{4}\)Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia
\(^{5}\)Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Victoria, Australia

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that is characterized by progressive weakness, paralysis and muscle loss often resulting in patient death within 3–5 years of diagnosis. Recently, we identified disease-linked mutations in the \(\text{CCNF}\) gene, which encodes the cyclin F protein, in cohorts of patients with familial and sporadic ALS and frontotemporal dementia (FTD) (Williams KL \textit{et al.} 2016 \textit{Nat. Commun.} \textbf{7}, 11253. (doi:10.1038/ncomms11253)). Cyclin F is a part of a Skp1-Cul-F-box (SCF) E3 ubiquitin-protein ligase complex and is responsible for ubiquitylating proteins for degradation by the proteasome. In this study, we investigated the phosphorylation status of cyclin F and the effect of the serine to glycine substitution at site 621 (S621G) on E3 ligase activity. This specific mutation (S621G) was found in a multi-generational Australian family with ALS/FTD. We identified seven phosphorylation sites on cyclin F, of which five are newly reported including Ser621. These phosphorylation sites were mostly identified within the PEST (proline, glutamic acid, serine and threonine) sequence located at the C-terminus of cyclin F. Additionally, we determined that casein kinase II (CK2) can phosphorylate Ser621 and thereby regulate the E3 ligase activity of the SCF\(^{(\text{cyclin F})}\) complex. Furthermore, the S621G mutation in cyclin F prevents phosphorylation by CK2 and confers elevated Lys48-ubiquitylation activity, a hallmark of ALS/FTD pathology. These findings highlight the importance of phosphorylation in regulating the activity of the SCF\(^{(\text{cyclin F})}\) E3 ligase complex that can affect downstream processes and may lead to defective motor neuron development, neuron degeneration and ultimately ALS and FTD.

1. Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative disorders that have common and convergent molecular and
pathogenic features [1]. ALS is characterized by progressive weakness, paralysis and muscle loss often resulting in patient death within 3–5 years of diagnosis [2]. Many studies of the biological mechanisms of ALS and FTD have used in vivo and in vitro models with genetic mutations found in familial cases to recapitulate features of the disease. Around 20% of ALS patients show signs of frontotemporal dementia (FTD) and segregation of both ALS and FTD may be seen within individual families, particularly those with mutations in C9ORF72 [3,4]. Familial ALS cases appear clinically indistinguishable from sporadic cases [5], and disease models that incorporate familial gene mutations offer an opportunity to better understand the biology of both familial and sporadic ALS. Genetic analyses of ALS-affected families have identified mutations in many genes, including SOD1, TARDBP, FUS, UBQLN2, VCP, OPTN and C9ORF72 [6–13]. The proteins encoded by these genes generally cluster into two major functional groups: RNA/DNA synthesis and processing (e.g. TDP-43 and FUS), and protein degradation pathways (such as UBQLN2) that lead to proteostasis dysfunction. The link between protein degradation pathways and ALS and FTD is additionally supported by the key pathological hallmark of insoluble proteinaceous inclusions of ubiquitylated proteins, including TDP-43 [14].

We have recently identified ALS–FTD linked mutations in the CCNF gene that occur at similar frequency to mutations in TARDBP [15]. A p.Ser621Gly (S621G) mutation was found to segregate across multiple generations in an Australian ALS/FTD family, and mutations in other sites across the protein were identified in ALS/FTD patients from the USA, Europe and Japan. Experimental expression of CCNF mutations identified from ALS/FTD patients led to defective protein degradation and signature features of ALS pathogenesis in vitro including elevated ubiquitylation and increased levels of ubiquitylated ribonucleotide reductase M2 (RRM2) and TDP-43 [15]. Cyclin F is a part of a Skp1-Cul-F-box (SCF) E3 ubiquitin-protein ligase complex which is an integral part of a cell’s recycling system that ubiquitylates substrates for degradation by the proteasome. Ubiquitylation is carried out in three main steps: activation by E1s, ubiquitin conjugation by E2s and substrate ligation by E3s. This sequential cascade is the tethering of ubiquitin to lysine residues on proteins via different ubiquitin linkages (such as lysine 48 (Lys48) or lysine 63 (Lys63)), which in turn directs the tagged protein for various purposes including signalling and degradation.

There are over 300 known E3 ligases [16], and it has become increasingly apparent that the activity and substrate selectivity of many E3 ligases is regulated by other post-translational modifications, including phosphorylation [17–20], indicating a convergence of molecular and signalling pathways. For example, phosphorylation of the C-terminus of mouse double minute 2 homolog (MDM2) by the kinase ataxia telangiectasia mutated (ATM) allosterically inhibits really interesting new gene (RING) domain oligomerization resulting in reduced ubiquitylation and stabilization of p53 after DNA damage [20]. Another example is the phosphorylation of Smurf1 at Thr306 by protein kinase A, which regulates its substrate preference during axonal development by preventing degradation of Par6 and increasing degradation of growth-inhibiting RHOA [19]. In the context of ALS and FTD, it was recently found that phosphorylation of TDP-43 by truncated casein kinase (CK) 1α triggers mislocalization and accumulation of TDP-43 within insoluble aggregates [21], which are the pathological hallmarks observed in most ALS and FTD patients [22]. Numerous kinases have been implicated in TDP-43 phosphorylation including CK1, CK1ε, CK2, CDC7 and TTBK1/2 [23–27].

In this study, we investigated the phosphorylation status of cyclin F and the effect of the S621G mutation on its E3 ligase Lys48-specific ubiquitylation activity. We used a phosphoproteomics workflow to identify several novel phosphorylation sites within cyclin F, and identified a key role of CK2 phosphorylation on Ser621 in regulation of SCF<sub>cyclin F</sub> E3 ligase activity. These findings provide insights into the molecular mechanisms of a newly discovered ALS/FTD gene CCNF, suggesting that the cyclin F<sub>S621G</sub> mutation affects Lys48-ubiquitylation activity, with potential consequences for protein degradation pathways that may drive disease development. The convergence of phosphorylation and disease-linked mutation of a single residue (S621G) indicates that this site is of particular importance for ALS/FTD.

2. Material and methods

2.1. Reagents

Antibodies used in this study were: rabbit polyclonal anti-cyclin F (1 : 300; cat# sc-952, Santa Cruz Biotechnology), mouse monoclonal anti-mCherry (1 : 300; cat# 632543, Clonotech), rabbit anti-mCherry (cat# ab183628, Abcam), rabbit anti-Skp1 p19 (H-163) (1 : 1000, cat# sc-7163, Santa Cruz Biotechnology), mouse monoclonal anti-β-tubulin (1 : 2000; cat# T0198, Sigma-Aldrich) and anti-phospho-CK2 substrate (1 : 1000, cat# 8783, Cell Signaling Technology). Rabbit antibodies against phosphocyclin F (immunogen: DQEpS5EAKEG) and pan-cyclin F (immunogen: DQEpSEGEKEG) were customized and purchased from Bethyl Laboratories. Recombinant casein kinase II was obtained from New England BioLabs. Plasmid DNA constructs were purchased from Genscript (Piscataway, NJ, USA).

2.2. Cell culture and transfection

Human embryonic kidney (HEK293) or Neuro-2a cell lines were plated at 1 × 10<sup>6</sup> cells in 100 mm plates and maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich) and 1% antibiotics (100 mg ml<sup>−1</sup> streptomycin and 100 U ml<sup>−1</sup> penicillin; Sigma-Aldrich) in a 37°C heat-jacket humidified incubator with 5% CO₂. Following 48 h of growth (approx. 80% confluence), HEK293 or Neuro-2a cells were transfected with DNA constructs as previously described [15]. Briefly, 7.5 μg of wild-type or mutant cyclin F<sub>S621C</sub> DNA fused to N-terminal mCherry was mixed with Lipofectamine 2000 (Life Technologies) and Opti-MEM (Life Technologies) for each plate and incubated at 37°C for 5 h. Cells were washed with warm PBS, re-fed with complete DMEM media and maintained for 24 h. Transfections were carried out in three biological replicates from different passages. For CK2 inhibition, cells were re-fed with complete DMEM media and treated for 18 h with CX4945 (4 μM) prior to harvesting. For CK2 RNAi knockdowns, 25 pmol of CK2a siRNA (Cat #6389, Cell Signaling Technology, MA, USA) was co-transfected under the same conditions with mCherry–cyclin F.
2.3. Cell lysis and immunoprecipitation

Cells were lysed and total protein was extracted with probe sonication (10 s, Setting 3, Branson Sonifier 450) in NP40 (1% (v/v) Nonidet P-40) in TBS (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) or RIPA (1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS in TBS) buffer containing 2 mM EDTA, 10 mM N-ethylmaleimide, Complete protease inhibitor cocktail (Roche) and PhosStop inhibitor cocktail (Roche). Cellular debris was pelleted at 16,000 g (30 min at 4°C). Protein concentration was estimated using the Pierce BCA Reagent (Pierce Biotechnology). Typically, 1 μg of antibody per 500 μg of protein extract in NP40 buffer was used for immunoprecipitations. Protein A/G magnetic beads (Pierce) were used to capture the antibody : protein complex. Immunoprecipitation mixtures were washed with TBS containing 1% (v/v) NP40 (3 × 3 min) to remove non-specifically bound proteins, and then resuspended in either (i) E3 ligase reaction buffer or (ii) 100 mM ammonium bicarbonate pH 8.0 for in-solution trypsin digestion and LC–MS/MS analyses. Triplicate immunoprecipitations were carried out from three biological transfected cell culture replicates.

2.4. One-dimensional SDS-PAGE and immunoblotting analyses

For one-dimensional SDS-PAGE, denatured proteins (20 μg) were separated on 4–12% Bis–Tris pre-cast gels using a 3-(N-morpholino) propane sulfonic acid (MOPS) running buffer (180 V, 125 mA) according to the manufacturer’s instructions (Invitrogen, MO, USA). One-dimensional SDS-PAGE separated proteins were transferred onto either nitrocellulose or PVDF membranes using the Bio-Rad Turbo Transfer apparatus (13 V, 1.3 A for 1 h) for mini-gels or cellulose or PVDF membranes using the Bio-Rad Turbo PAGE separated proteins were transferred onto either nitrocellulose or PVDF membranes using the Bio-Rad Turbo Transfer apparatus (13 V, 1.3 A for 7 min for mini-gels or 15 cm, 5 V for full-gels). Blots were blocked with 3% (w/v) skim milk in TBS/T for 1 h and washed in TBS/T (3 ×). Primary antibodies were diluted in 3% (w/v) BSA in TBS/T and incubated with blots overnight at 4°C.

After incubation, membranes were washed in PBS/T (3 × 1 for 10 min each before fluorescently labelled IRDye 800CW goat anti-rabbit IgG (1:10,000) was applied for 1 h at room temperature. Proteins were imaged using a Li-Cor Odyssey imaging system at the appropriate wavelength. Densitometry analysis was conducted using ImageJ software (v. 1.47; National Institutes of Health) [28] and statistics were conducted using Microsoft Excel. Graphs were made using GraphPad Prism 5 and Microsoft Excel.

2.5. In vitro phosphorylation by casein kinase II

In vitro phosphorylation of naked DQSEGEKEG peptide (Synpeptide, Shanghai, China) was carried out according to the manufacturer’s instructions (New England BioLabs, MA, USA). Briefly, the naked peptide (0.2 mg) was resuspended in 180.6 μL of MilliQ water (1 nmol μL⁻¹). Approximately 0.1 nmol of peptide was added to the reaction buffer (50 mM Tris-HCl, 10 mM MgCl₂, 0.1 mM EDTA, 2 mM DTT, 0.01% Brij 35, pH 7.5) with recombinant CK2 (250 U) and 400 μM ATP. The in vitro phosphorylation assay was carried out in triplicate and incubated at 30°C for 2 h. Inhibition of CK2 phosphorylation was carried out in the presence of CX4945 (4 μM). The reaction mixture was stopped by addition of 2% (v/v) formic acid, desalted using a C₁₈ Sep-Pak and eluted in 90% ACN, 0.1% formic acid and dried under vacuum centrifuge.

2.6. Trypsin, Asp-N digestion and titanium dioxide (TiO₂) enrichment

Immunoprecipitated proteins were reduced and alkylated with 10 mM DTT and 55 mM iodoacetamide respectively, and digested with trypsin or Asp-N (1:50 enzyme : protein) overnight at 37°C. The digestion was inactivated by the addition of 2 μL of formic acid (final concentration 2% (v/v) formic acid). Tryptic or Asp-N digested peptides were cleaned and enriched on a pre-equilibrated C₁₈ Sep-Pak cartridge and eluted in 90% ACN, 0.1% formic acid and dried under vacuum centrifugation.

Lyophilized peptides were resuspended in 80 mg mL⁻¹ glycolic acid, 80% (v/v) ACN, 5% (v/v) TFA and added to TiO₂ beads (5 mg; GL Sciences, Japan) prewashed in the same solution [29]. The mixture was incubated for 1 h at room temperature with mixing at 1400 r.p.m., and centrifuged at 800g to recover the beads. The supernatant was removed and re-added to a fresh batch of TiO₂ beads and repeated. TiO₂ beads from both incubations were washed 2 × in 80 mg mL⁻¹ glycolic acid, 80% (v/v) ACN, 5% (v/v) TFA, 2 × in 80% (v/v) ACN, 1% (v/v) TFA, and 1 × in 20% (v/v) ACN, 0.1% (v/v) TFA. The beads were briefly dried under vacuum centrifuge. Phosphopeptides were eluted sequentially with 1% NH₄OH, 1% NH₄OH/30% ACN and 1% NH₄OH/50% ACN. The combined eluates were pooled and lyophilized under vacuum centrifugation.

2.7. LC–MS/MS

Peptide fractions were injected onto a 2 cm desalting trap column packed with YMC C₁₈ material (75 μm ID, 5–15 μm, 120 A) at 5 μL min⁻¹ for 6 min before being eluted onto an analytical column packed with Michrom Magic C₁₈ (75 μm × 15 cm, 5 μm, 120 A) using a nanoLC system (Thermo) using a nanoflow solvent delivery of 300 nL min⁻¹. Each sample was separated on a 60 min gradient (25%–50% v/v acetonitrile, 0.1% formic acid) with a flow rate of 300 nL min⁻¹. The peptides were eluted and ionized into a Q-Exactive or LTQ Orbitrap Velos mass spectrometer (Thermo Fisher). The electrospray source was fitted with an emitter tip 10 μm (New Objective, Woburn, MA) and maintained at 2.5 kV electrospray voltage. Precursor ions were selected for MS/MS fragmentation using a data-dependent ‘Top 10’ method operating in FTMS acquisition mode with HCD (Q-Exactive) or CID (Orbitrap) fragmentation. Precursor ions were selected for MS/MS fragmentation using a data-dependent ‘Top 10’ method operating in FT–FT acquisition mode with CID or HCD fragmentation. IT-MS and FT-MS on the Orbitrap Velos was carried out with a survey scan range between m/z 350–1800 Da with MS/MS threshold of 500 ions for CID, and MS/MS threshold of 5000 ions for HCD, with an isolation width of 2.0 Da and normalized collision energy of 35%. FT-MS analysis on the Q-Exactive was carried out with a 35,000 resolution and an AGC target of 1 × 10⁶ ions in full MS, and MS/MS scans were carried out at 17,500 resolution with an AGC target of 2 × 10⁷ ions. Maximum injection times were set to 120 and 60 ms, respectively. The ion
Selection threshold for triggering MS/MS fragmentation was set to 25,000 counts and an isolation width of 1.9 Da was used to perform HCD fragmentation with normalized collision energy of 27%.

Spectra files (*.RAW) were processed using the PROTEOME DISCOVERER 1.4 software (Thermo Finnigan, CA, USA) incorporating the Mascot search algorithm (Matrix Sciences, UK). Peptide identifications were determined using a 10 ppm precursor ion tolerance and a 0.05 Da MS/MS fragment ion tolerance. Carbamidomethylation modification of cysteines was considered a static modification while oxidation of methionine, acetyl modification on N-terminal residues and phosphate on serine, threonine and tyrosine were set as variable modifications. MS/MS spectra were searched through PROTEOME DISCOVERER (Thermo Scientific) using the Mascot algorithm against the UniProt Homo sapiens database (sequences 15742024, 7 May 2012). The protein sequence for the mutated cyclin F<sup>S621G</sup> was added manually to a custom database which included the UniProt sequences. The data were processed within the PROTEOME DISCOVERER software. Phosphosite occupancy was validated using the PhosphoRS 3.1 node within the PD 1.4 with a fragment mass tolerance of 0.5 Da [30]. The data has been deposited to the ProteomeXchange with identifier PXD004531.

### 2.8. E3 ligase activity assay

E3 ligase activity was determined using the E3LITE Customisable Ubiquitin Ligase ELISA Kit (LifeSensors, PA, USA) as per the manufacturer’s instructions. UBE2D3 was selected as the E2 enzyme and Lys48-ubiquitin was selected as the ubiquitin substrate. Briefly, empty mCherry vector, mCherry–cyclin F or pre-immune rabbit control IgG were immunoprecipitated from transfected HEK293 cells as described above. Protein A/G beads were washed (3×) in 100 mM Tris-HCl (pH 8.0), 10 mM MgCl₂ and resuspended in 25 μl assay buffer (100 mM Tris-HCl, 10 mM MgCl₂, 0.2 mM DTT, pH 8.0). Immunoprecipitated mCherry, mCherry–cyclin F<sup>WT</sup>, mCherry–cyclin F<sup>S621G</sup> and pre-immune rabbit control IgG were used for activity assays.
Figure 2. Cyclin F Ser621 is phosphorylated. mCherry – cyclin F from transfected HEK293 cells was immunoprecipitated for phosphorylation analysis (a) MS/MS spectra of mutated Asp-N digested cyclin F peptide 618DQEGEGEKEG627; (b) MS/MS spectra of Asp-N digested wild-type cyclin F peptide 618DQEpSEGEKEG627; (c) MS/MS spectra of synthetic cyclin F peptide DQEpSEGEKEG showing almost identical b- and y-ions to the spectra shown in (b); (d) MS/MS spectra of phosphatase treated wild-type cyclin F, followed by Asp-N digestion showing complete removal of phosphate prior to MS analysis; and (e) cyclin FWT and cyclin FS621G were immunoblotted using custom rabbit antibodies raised against DQEpSEGEKEG (phospho) and DQESEGEKEG (pan) confirming the phosphorylation status at Ser621 and reduced phosphorylation by 0.37-fold ($p = 0.0035$, $n = 3$, Student’s t-test).

Table 1. Cyclin F phosphorylation sites. Two digestion strategies: trypsin and Asp-N were used to digest immunoprecipitated mCherry – cyclin F from transfected HEK293 or Neuro-2a cells. Seven phosphorylation sites were identified, of which five have not been reported and are located within the PEST sequence of cyclin F. Group-based prediction system (GPS) was used to predict upstream kinases of each phosphorylation site identified.

| phosphopeptide sequence       | start | end | site   | predicted upstream kinase |
|-------------------------------|-------|-----|--------|---------------------------|
| ENpSLQEDR (trypsin)           | 575   | 582 | S577   | AKT                       |
| DGRSPVTpTpfTAEQSEETLGSLF (Asp-N) | 581 | 605 | T588   | CAMK                      |
| DGRSPVTpTpfTAEQSEETLGSLF (Asp-N) | 581 | 605 | T590   | CAMK                      |
| DQESEGEKEG (Asp-N)            | 618   | 627 | S621   | CK2                       |
| DVTGSSYSSVaspSPTSSV (Asp-N)   | 696   | 714 | S709   | P38 MAPK                  |
| DVTGSSYSSVaspSPTSSV (Asp-N)   | 696   | 714 | S713   | P38 MAPK                  |
| SCLQRPpgPSPPESVPPQQV (trypsin)| 745   | 766 | S754   | CDK4/5                    |

*a Unique phosphorylation site.
were then added to wells containing the Enzyme cocktail (E1 activating enzyme, E2 conjugating enzyme UBE2D3 and recombinant Lys48-ubiquitin). Each ligase reaction was activated by the addition of ATP (0.4 mM) and incubated at RT for 30 min. Each well was washed with PBS/T (3×), incubated with detection solution 1 for 60 min at RT, followed by incubation with streptavidin–HRP for 60 min at RT. Luminescence was read on a FLUOstar OPTIMA reader (BMG Labtech).

3. Results and discussion

In this study, we identified that Ser621 on SCF(cyclin F) was phosphorylated and required for regulating its Lys48-specific E3 ligase activity. We determined that phosphorylation at Ser621 is carried out by CK2, and inhibition of CK2 with CX4925 blocks phosphorylation at this site and subsequently Ser621 is carried out by CK2, and inhibition of CK2 with CX4925 blocks phosphorylation at this site and subsequently elevates SCF(cyclin F) E3 ligase activity. Further, a phosphomimetic created by mimicking constitutive phosphorylation of Ser621 through mutation to an aspartic acid (S621D) led to reduction in the ubiquitylation activity of cyclin F. Therefore, phosphorylation at Ser621 appears to act as a signal for cyclin F to suppress its E3 ligase activity, which can be regulated by controlling CK2 kinase activity or CK2 gene expression. Notably, we demonstrate that a recently identified S621G mutation in cyclin F which causes ALS/FTD [15] also leads to overactivity in the ubiquitylation activity of cyclin F, because Ser621 cannot be phosphorylated. The significance of this finding is that it suggests that abnormal phosphorylation of Ser621 in cyclin F may perturb cellular homeostasis leading to abnormal hyperubiquitylation of proteins, contributing to the aetiology of ALS/FTD.

3.1. The ubiquitylation E3 ligase activity of cyclin F is regulated by phosphorylation

The SCF(cyclin F) complex is one of the many E3 ligases that are responsible for ubiquitylating proteins for UPS degradation. Using a commercial ELISA, we screened for four different E2 conjugating enzymes (UBE2D3, UBE2L3, UBE2R1, UBE2E3) that promiscuously select a large range of substrates [31] (figure 1a). Neither UBE2L3 nor UBE2R1 showed Lys48-ubiquitylation activity, suggesting that these two E2s did not form the E1–E2–E3 triad with the immunoprecipitated SCF(cyclin F) complex. UBE2E3 showed E2 Lys48-conjugation activity approximately twofold above the background (no E2) \( \frac{2.5}{0.8} = 3 \). Based on these data, UBE2D3 was selected as the E2 conjugating enzyme to be used in downstream E3 ligase activity assays. Immunoblots were carried out following E3 ligase activity assays to demonstrate equivalent levels of immunoprecipitated mCherry–cyclin F used for activity assays (figure 1a).

To determine the E3 ligase activity, wild-type and ALS/FTD mutant cyclin F\(_{621G}\) were immunoprecipitated from transfected HEK293 cells, treated with Antarctic phosphatase to remove phosphate, and the Lys48-specific E3 ligase activity was measured on bead by ELISA. The E3 ligase activity of mutant cyclin F\(_{621G}\) was approximately 1.3-fold more active than wild-type cyclin F \( \frac{3.0}{2.3} = 1.3 \). Given that serine residues are well-described phosphosites that often regulate enzymatic activity, this suggests that the phosphorylation of the Ser621 site might regulate ubiquitylation activity of cyclin.
Figure 4. Casein kinase II phosphorylation regulates SCF(cyclin F) Lys48-specific E3 ligase activity. (a) E3 ligase activity of Lys48-ubiquitylation from immunoprecipitated mCherry–cyclin F in transfected cells treated with CX4945 (4 μM) demonstrated elevated ubiquitylation activity with CK2 inhibition by approximately 1.35-fold \((p = 0.0215, n = 3, \text{one-way ANOVA})\). Immunoblots were carried out following E3 ligase activity assays to demonstrate equivalent levels of immunoprecipitated mCherry–cyclin F used for activity assays, which also revealed cyclin F contained a CK2 phosphorylation motif. (b) Immunoblot analysis of phospho-cyclin F (Ser621) using custom antibodies revealed reduced phosphorylation by approximately 0.68-fold \((p = 0.0154, n = 3, \text{one-way ANOVA})\) with CX4945 treatment. Vertical dashed line indicates cropped lanes. (c) E3 ligase activity of Lys48-ubiquitylation from immunoprecipitated mCherry–cyclin F in cells co-transfected with mCherry–CCNFWT or mCherry–CCNF621G with scramble or CK2 siRNA demonstrated elevated ubiquitylation activity with CK2 knockdown by approximately 1.2-fold \((p = 0.0136, n = 3, \text{one-way ANOVA})\). Immunoblots were carried out following E3 ligase activity assays to demonstrate equivalent levels of immunoprecipitated mCherry–cyclin F used for activity assays. (d) Immunoblot analysis of phospho-cyclin F (Ser621) using custom antibodies revealed reduced phosphorylation by approximately 0.61-fold \((p = 0.005, n = 3, \text{one-way ANOVA})\) with CK2 RNAi knockdown. Data are represented as the mean ± s.e.m. using one-way ANOVA with Tukey’s post hoc test.
F (and, therefore, loss of this phosphosite through the S621G mutant increases ubiquitylation activity). Accordingly, following complete dephosphorylation the E3 ligase activity of immunoprecipitated SCF\(^{\text{cyclin F}}\) was significantly decreased in both mutant and wild-type cyclin F (figure 1b). This effect was greater in the wild-type (2.3-fold, \(p = 0.0004, n = 3\)) than the mutant cyclin F\(^{\text{S621G}}\) (1.3-fold, \(p = 0.0183, n = 3\)). This led us to speculate that the activity of the SCF\(^{\text{cyclin F}}\) complex was regulated by phosphorylation of multiple sites, including Ser621, which would explain the difference seen in the decreased activity of wild-type compared with mutant cyclin F\(^{\text{S621G}}\) following dephosphorylation. Immunoblots were carried out following E3 ligase activity assays and demonstrated that the ubiquitylation activity measurements were performed on equivalent levels of immunoprecipitated mCherry–cyclin F (figure 1b).

### 3.2. Identification of phosphosites in cyclin F

The in vitro ubiquitylation assays (figure 1) suggest that Ser621 might be a phosphorylation site that regulates about 30% of the ubiquitylation activity of cyclin F, which was confirmed by predictions using NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/). NetPhos predicted with high confidence 88 potential phosphorylation sites in cyclin F, which included Ser621. To determine phosphorylation sites on cyclin F, transfected mCherry–cyclin F was enriched by immunoprecipitation, digested with trypsin, phosphopeptides enriched by TiO\(_2\) beads, and analysed by LC–MS/MS. Using this digestion procedure, we identified two phosphorylation sites on cyclin F at Ser577 and Ser754 (table 1). The regions surrounding Ser621 do not contain lysine or arginine residues that are required for producing appropriate length tryptic peptides for LC–MS. Instead, we employed Asp-N protease to digest cyclin F, enriched Asp-N digested peptides using TiO\(_2\) and subjected them to LC–MS/MS. Using this strategy we observed specific diagnostic ions and loss of phosphate ions (PO\(_4\)) to detect an additional four phosphosites on cyclin F: Thr588, Thr590, Ser621, Ser709 and Ser713 \[32\] (table 1).

The phosphorylation status of immunoprecipitated mCherry–cyclin F containing the S621G mutation (figure 2a) and wild-type mCherry–cyclin F\(^{\text{WT}}\) (figure 2b) was confirmed by MS/MS fragmentation. To verify this phosphorylated sequence, we subjected a synthetic phosphorylated (figure 2c) and unphosphorylated (not shown) versions of the Asp-N digested peptide (DQESEGEKEG) to LC–MS/MS. We confirmed the MS/MS fragmentation spectra matched between both synthetic and immunoprecipitated peptides. We also immunoprecipitated mCherry–cyclin F and dephosphorylated the IP prior to LC–MS/MS analysis and observed MS/MS fragmentation patterns that were reminiscent of the unphosphorylated version of the peptide (figure 2d), further confirming that Ser621 is a phosphorylation site. The MS/MS spectra that confirm the phosphosites described in table 1 are available on the ProteomeXchange with identifier PXD004531.

Using an alternative method, we examined the phosphorylation of cyclin F by immunoblots using customized antibodies raised against the phosphopeptide sequence DQESEGEKEG and non-phosphorylated DQESEGEKEG (Bethyl Laboratories). Although there was very minor non-specific reactivity observed with the phospho-specific cyclin F antibody, we verified that cells expressing only mCherry–cyclin F\(^{\text{WT}}\) were phosphorylated at Ser621 with negligible amounts detected in the mutant cyclin F\(^{\text{S621G}}\) and empty vector transfected cells (figure 2e). We detected reduced phosphorylation by approximately 0.37-fold (\(p = 0.0035, n = 3\)) of phospho-specific signal in cyclin F\(^{\text{S621G}}\) mutant cell lysates compared with cyclin F\(^{\text{WT}}\) lysates (figure 2e). We predicted that the non-phospho-specific antibody would detect less of the mutant cyclin F\(^{\text{S621G}}\) than the wild-type cyclin F, and confirmed that the antibody reactivity observed was indeed cyclin F. These data confirm the mass spectrometric identification of phosphorylated cyclin F at Ser621. Taken together, using both trypsin and Asp-N digestion approaches seven phosphorylation sites were identified, of which five have not been reported previously (S577, T588, T590, S621, S709) and two have been previously characterized (S713, S754) \[32,33\] (table 1). The phospho-specific antibody to cyclin F was able to distinguish between phosphorylated wild-type and mutant cyclin F, and therefore we used this antibody for further validation to determine the relative level of cyclin F phosphorylation upon cell treatments.

### 3.3. Casein kinase II phosphorylates cyclin F at Ser621

Many SCF complexes function by ubiquitylating substrates in a phosphorylation-dependent manner \[34\] such that the cyclin-dependent kinase (CDK) catalytic subunits are used to phosphorylate substrates and the F-box protein acts as a receptor to recruit phosphorylated substrates to the complex \[35\]. For example, phosphorylated cyclin D1 (Thr286) is
ubiquitylated by SCF(FBX4-alphaB crystallin) prior to proteolysis and is required for regulating cell cycle progression such that impairment of SCF(FBX4-alphaB crystallin) function attenuates cyclin D1 ubiquitylation, promoting cyclin D1 overexpression and accelerated cell-cycle progression [36]. Cyclin F does not bind CDKs and instead a hydrophobic patch within its cyclin box domain binds a CY motif (RxL/RxI) in the substrate [37]. Therefore, cyclin F is not phosphorylated by the canonical series of cyclin-dependent kinases and must be modified by kinases that are independent of cell-cycle regulation to ultimately regulate the SCF(cyclin F) complex. Using the group-based prediction system (GPS) [38], numerous MAPks, CDKs and NEKs were identified as potential kinases that could phosphorylate the newly identified phosphosites in cyclin F (table 1).

Casein kinase II (CK2) was predicted to phosphorylate Ser621 with the surrounding sequences falling within the CK2 substrate motif (S–X–X–D/E). Using the synthetic naked peptide (DQESEGEKEG) which eluted at 7.6 min (figure 3a), we performed an in vitro phosphorylation assay with recombinant CK2 and ATP. The reaction was analysed by LC–MS/MS, which revealed phosphorylation on serine within the synthetic peptide that corresponds to Ser621 in cyclin F that eluted at 7.9 min (figure 3b). We repeated the in vitro phosphorylation assay in the presence of the CK2 inhibitor CX4945 and analysed the reaction by LC–MS/MS (figure 3c). Using extracted ion chromatograms (EICs) and matching retention times of 7.6 and 7.9 min to respectively identify the unphosphorylated and phosphorylated peptides and their specific masses, a mixture of 45% naked DQESEGEKEG peptide (m/z 554.2) and 55% phosphorylated DQEpSEGEKEG peptide (m/z 594.2) was observed. CX4945 treatment decreased recombinant CK2 phosphorylation activity by approximately 55% based on area-under-curve measurements (figure 3d). We suspect that the incomplete inhibition of CK2-mediated phosphorylation of Ser621 by CX4945 was likely caused by the presence of a 100-fold higher concentration of ATP than CX4945 (which was required for the in vitro ubiquitylation assay), as CX4945 acts by blocking the ATP-binding site in CK2 (and therefore CX4945 and ATP are competing for the same site in CK2) [39]. Attempts to overcome this by performing the assay with lower concentrations of ATP interfered with the quality of the ubiquitylation assay (results not shown), and so we were unable to confirm this experimentally. These results demonstrate that CK2 can phosphorylate the serine within the synthetic DQESEGEKEG peptide, corresponding to amino acids 618–627 of cyclin F. Combined with the bioinformatics predictions, this provides evidence that CK2 has the ability to phosphorylate Ser621 within cyclin F in cells.

Next, we examined SCF(cyclin F) E3 ligase activity in the presence of CK2 inhibition by transfecting HEK293 cells with cyclin F WT and cyclin F S621G followed by treatment with CX4945 for 18 h. In cells treated with CX4945, immunopurified cyclin F WT had approximately 1.35-fold elevated Lys48-ubiquitylation activity compared with the vehicle controls (figure 4a), while CX4945 treatment did not affect the activity of immunopurified mutant cyclin F S621G based on E3 ligase activity assays. We verified that equivalent levels of immunoprecipitated mCherry–cyclin F were used in the ubiquitylation assay, by probing for mCherry and cyclin F at the completion of the E3 ubiquitylation activity assays (figure 4b). We immunoblotted transfected cell lysates treated with CX4945 using the phospho-specific cyclin F (Ser621) antibody, and observed approximately 32% less Ser621 phosphorylation (p = 0.0154, n = 3) in CX4945 treated cyclin F WT cells (figure 4c). To confirm that the CX4945 effectively impairs CK2 activity in these cell-based assays, we performed immunoblotting analyses to detect CK2 phosphorylated substrates containing the S–X–X–D/E motif. Inhibition of CK2 activity by CX4945 resulted in approximately 39% and 37% decreased phosphorylation of substrates in cells transfected with cyclin F WT and cyclin F S621G, respectively. The detection of residual CK2 substrates in cells treated with CX4945 is likely due to: (i) endogenous CK2 phosphorylation events that occurred prior to CX4945.
treatment because CK2 is constitutively active regulating numerous cellular processes [40] and/or (ii) incomplete inhibition of CK2 phosphorylation activity by CX4945 as described earlier (figure 3d).

This finding was recapitulated with siRNA-mediated knockdown of CK2α expression in cells expressing mCherry–cyclin FWT and mCherry–cyclin F621G. In cells expressing cyclin FWT, with CK2 knockdown, we observed a statistically significant approximately 20% increase (p = 0.0136, n = 3) in E3 ligase activity (figure 4c). We immunoblotted for phospho-specific cyclin F at Ser621 from transfected cell lysates, and observed approximately 0.61-fold less Ser621 phosphorylation (p = 0.005, n = 3) in CK2 RNAi knockdown cells expressing cyclin FWT compared with those with scramble siRNA control, further suggesting that CK2 is capable of phosphorylating this site (figure 4d).

In this study, we predicted and subsequently confirmed that CK2 phosphorylates Ser621 and, therefore, has a role in regulating the E3 ligase activity of cyclin F. This is important because we have recently identified an ALS/FTD-causing S621G mutation in cyclin F, which presumably prevents phosphorylation of Ser621, resulting in elevated activity of cyclin F621G that may contribute to the abnormal hyperubiquitylation of proteins, which are a hallmark pathology of ALS and FTD. This suggests that phosphorylation of Ser621 serves to turn off cyclin F activity. To confirm this, we generated a phosphomimetic by mutating Ser621 to an aspartic acid (S621D). As expected, the phosphomimetic cyclin F621D was approximately 0.8-fold less active than the wild-type cyclin F (p = 0.0367, n = 3) (figure 5). The conversion to an aspartic acid in place of a phosphorylated serine that is chemically similar confers a net negative charge rendering this site as being ‘constitutively phosphorylated’, which resulted in a reduction of E3 ligase activity.

We present a series of biochemical data that collectively suggest that CK2 phosphorylation of cyclin F at Ser621 is crucial for regulating SCF(cyclin F) complex E3 ligase activity. Notably, the ALS/FTD-causing S621G missense mutation confers elevated E3 ligase activity (figure 6). Our findings suggest that precisely regulated phosphorylation of Ser621 in cyclin F is crucial for the maintenance of appropriate activity of ubiquitylation-dependent protein degradative pathways. These pathways are often impaired in neurodegenerative diseases such as ALS and FTD, indicating that mutation of Ser621 and altered phosphorylation status of cyclin F is likely one of the upstream pathogenic causes of these diseases.

Data accessibility. Mass spectrometry data has been deposited to the ProteomeXchange with identifier PXD004531 (username: reviewer 75905@ebsi.eauni; password: 112Y2z5w).

Authors’ contributions. A.L. carried out all the experiments, conception and design of the study, acquisition and analysis of data and wrote the manuscript. S.L.R., S.S.L.G. and A.D. carried out experiments in figures 1, and 4–6, acquired data and contributed to the design of the studies. M.M., V.S., S.Y., K.L.W., E.K.D., A.K.W., K.Y.Z., B.S., A.R., H.S., J.J.Y., N.J.C. and J.D.A. contributed to the technical design of experiments and preparation of the manuscript. I.P.B., M.P.M. and R.S.C. contributed intellectually to conception and design of all the experiments and preparation of the manuscript. All authors reviewed the results and approved the final version of the manuscript.

Competing interests. The authors declare no conflicts of interests.

Funding. This research was supported by funding from the Motor Neurone Disease Research Institute of Australia (MNDRIA): Mick Rodger Benalla Research Grant (1510) and MNDRIA grant-in-aid (1628, 1715); MND Australia and National Health and Medical Research Council of Australia (NHMRC) grants: APP1107644 and APP1095215 and early career fellowship APP1036835.

Acknowledgements. Aspects of this research were supported by access to the Australian Proteomics Analysis Facility (APAF) established under the Australian Government’s NCRIS programme. The authors acknowledge the support of the Macquarie University Centre for Motor Neuron Disease Research.

References

1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. 2011 Amyotrophic lateral sclerosis. Lancet 377, 942 – 955. (doi:10.1016/S0140-6736(10)61156-7)
2. Hardiman O, van den Berg LH, Kiernan MC. 2011 Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7, 639 – 649. (doi:10.1038/nrneurol.2011.153)
3. Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. 2007 TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch. Neurol. 64, 1388 – 1394. (doi:10.1001/archneurol.64.10.1388)
4. Bigio EH et al. 2013 Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 125, 463 – 465. (doi:10.1007/s00401-013-1089-6)
5. Gros-Louis F, Gaspar C, Rouleau GA. 2006 Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 956 – 972. (doi:10.1016/j.bbadis.2006.01.004)
6. Renton AE et al. 2011 A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257 – 268. (doi:10.1016/j.neuron.2011.09.010)
7. DeJesus-Hernandez M et al. 2011 Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245 – 256. (doi:10.1016/j.neuron.2011.09.011)
8. Maruyama H et al. 2010 Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223 – 226. (doi:10.1038/nature08971)
9. Johnson JO et al. 2010 Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857 – 864. (doi:10.1016/j.neuron.2010.11.036)
10. Deng HX et al. 2011 Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211 – 215. (doi:10.1038/nature10533)
11. Vance C et al. 2009 Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208 – 1211. (doi:10.1126/science.1165942)
12. Sreedharan J et al. 2008 TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668 – 1672. (doi:10.1126/science.1154584)
13. Rosen DR. 1993 Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364, 362. (doi:10.1038/364362a0)
14. Neumann M et al. 2006 Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130 – 133. (doi:10.1126/science.1134108)
15. Williams KL et al. 2016 C9orf72 mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun. 7, 11253. (doi:10.1038/ncomms11253)
16. Li W et al. 2008 Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling. PLoS ONE 3, e1487. (doi:10.1371/journal.pone.0001487)
17. Yang C, Zhou W, Jeon MS, Demydenko D, Harada Y, Zhou H, Liu Y-C. 2006 Negative regulation of the E3 ubiquitin ligase Itch via Fyn-mediated tyrosine...
phosphorylation. *Mol. Cell* **21**, 135–141. (doi:10.1016/j.molcel.2005.11.014)

18. Stacey KB, Breen E, Jeffreies CA. 2012 Tyrosine phosphorylation of the E3 ubiquitin ligase TRIM21 positively regulates interaction with IRF3 and hence TRIM21 activity. *PloS ONE* **7**, e34041. (doi:10.1371/journal.pone.0034041)

19. Cheng PL, Lu H, Shelly M, Gao H, Poo MM. 2011 Phosphorylation of E3 ligase Smurf1 switches its substrate preference in support of axon development. *Neuron* **69**, 231–243. (doi:10.1016/j.neuron.2010.12.021)

20. Cheng Q, Cross B, Li B, Chen L, Li Z, Chen J. 2011 Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. *Mol. Cell. Biol.* **31**, 4951–4963. (doi:10.1128/MCB.00553-11)

21. Nonaka T et al. 2016 Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated caspein kinase 1 delta triggers mislocalization and accumulation of TDP-43. *J. Biol. Chem.* **291**, 5473–5483. (doi:10.1074/jbc.M115.695379)

22. Kametani F, Obi T, Shishido T, Akatsu H, Murayama S, Saito Y, Yoshida M, Hasegawa M. 2016 Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. *Sci. Rep.* **6**, 23281. (doi:10.1038/srep23281)

23. Liachko NF et al. 2014 The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. *PloS Genet.* **10**, e1004803. (doi:10.1371/journal.pgen.1004803)

24. Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JR, Kraemer BC. 2013 CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. *Ann. Neurol.* **74**, 39–52. (doi:10.1002/ana.23670)

25. Liachko NF, Guthrie CR, Kraemer BC. 2010 Phosphorylation promotes neurotoxicity in a C. *narcissus* model of TDP-43 proteinopathy. *J. Neurosci.* **30**, 16 208–16 219. (doi:10.1523/JNEUROSCI.2911-10.2010)

26. Choksi DK, Roy B, Chatterjee S, Yusuff T, Bakhoun MF, Sengupta U, Ambegaokar S, Kayed R, Jackson GR. 2014 TDP-43 phosphorylation by caspein kinase lep1 promotes oligomerization and enhances toxicity in vivo. *Hum. Mol. Genet.* **23**, 1025–1035. (doi:10.1093/hmg/ddt498)

27. Carlomagno Y et al. 2014 Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. *PloS ONE* **9**, e90452. (doi:10.1371/journal.pone.0090452)

28. Schneider CA, Rasband WS, Eliceiri KW. 2012 NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675. (doi:10.1038/nmeth.2089)

29. Thingholm TE et al. 2006 Highly selective enrichment of phosphorylated peptides using titanium dioxide. *Nat. Protoc.* **1**, 1929–1935. (doi:10.1038/nprot.2006.185)

30. Taus T, Kocher T, Fichter P, Paschke C, Schmidt A, Henrich C, Mechtler K. 2011 Universal and confident phosphorylation site localization using phosphoRS. *J. Proteome Res.* **10**, 5354–5362. (doi:10.1021/pr200611n)

31. Brzovic PS, Klevecz RE. 2006 Ubiquitin transfer from the E2 perspective: why is UbcH5 so promiscuous? *Mol. Cell* **24**, 355–366. (doi:10.1016/j.molcel.2006.09.007)

32. Schulman BA, Lindstrom DL, Harlow E. 1999 Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. *Proc. Natl. Acad. Sci. USA* **95**, 10 453–10 458. (doi:10.1073/pnas.95.18.10453)

33. Xue Y, Ren J, Gao X, Jin C, Wen L, Yao X. 2008 GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. *Mol. Cell. Proteomics* **7**, 1598–1608. (doi:10.1074/mcp.M700574-MCP200)

34. Siddiqui-Jain A et al. 2010 CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. *Cancer Res.* **70**, 10 288–10 298. (doi:10.1158/0008-5472.CAN-10-1893)

35. Litchfield DW. 2003 Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. *Biochem. J.* **369**, 1–15. (doi:10.1042/ bj20021469)